Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 19206012 | HLA-A*24 | bone disease | NA | NA | NA | unclassified | |
| she received weekly intradermal injection with hla-a*2404-restricted, 9-mer wt1 peptide against residual bone disease. | |||||||
| 21708733 | HLA (HLA) | thalassemias | NA | NA | NA | unclassified | |
| evidence for genome-shaping interactions can be found in the geographic and ethnic distributions of the hemoglobins, blood group antigens, thalassemias, red cell membrane molecules, human lymphocyte antigen (hla) classes, and cytokines. | |||||||
| 14634793 | HLA-B*35 | malt lymphoma | German | NA | NA | negative | |
| decreased frequency of hla-b35 in patients with gastric malt lymphoma. | |||||||
| 14634793 | HLA (HLA) | malt lymphoma | German | NA | NA | only_studied | |
| to evaluate the association between hla type and malt lymphoma, we investigated 46 patients with malt lymphoma recruited in a prospective multicenter study from october 1998 to march 2001. | |||||||
| 14634793 | HLA-B*35 | malt lymphoma | German | NA | NA | lack_of_evidence | |
| exploratory statistical analysis using fisher's exact test showed significantly decreased frequency of hla-b35 in the malt lymphoma group compared to the control group. | |||||||
| 14634793 | HLA-B*35 | malt lymphoma | German | NA | NA | unclassified | |
| our data suggest a negative association between hla-b35 and malt lymphoma; however, larger studies are necessary to confirm a protective role of this hla antigen. | |||||||
| 25298310 | HLA-DRB1*15 | primary progressive multiple sclerosis | NA | NA | NA | unclassified | |
| hla-drb1*15 typing was performed in 41 patients with primary progressive multiple sclerosis (ppms) who were recruited within 5 years of symptom onset. | |||||||
| 14673379 | HLA-B*27 | back pains | NA | NA | NA | unclassified | |
| sto report a very rare cause of back pain.summary of datafop is an autosomal dominant disorder with overexpression of bone morphogenetic protein 4 and negative hla b27. | |||||||
| 14676113 | HLA-A*02 | hepatocellular cancer | NA | NA | NA | unclassified | |
| t-cell responses to hla-a*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. | |||||||
| 16785570 | HLA-A*02 | hepatocellular cancer | NA | NA | NA | unclassified | |
| the four immunodominant epitopes have been tested for immunogenicity in vivo, in hla-a*0201+afp+ advanced stage hepatocellular cancer (hcc) patients, and have activated and expanded afp-specific ifn-gamma-producing t cells in these patients, despite high serum levels of this self ag. | |||||||
Copyright 2024